TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: CD30 CAR-T cells have been shown to suppress tumor growth and increase tumor cell lysis in preclinical PTCL models [91], and led to durable remission in a single patient with EATL that was relapsed/refractory to multiple lines of chemotherapy, brentuximab vedotin, and ASCT [92].